Natera (NTRA) is back in focus after agreeing to supply its Latitude molecular residual disease test for Kupando Therapeutics’ Phase 1 trial of lead immunotherapy KUP-101 in advanced skin cancers.

The Kupando trial agreement comes after a very strong run in Natera’s stock, with a 30 day share price return of 14.2% and a 90 day share price return of 60.97%. The 1 year total shareholder return of 90.12% and very large 3 year total shareholder return suggest momentum has been building around the story.

If this kind of oncology driven growth theme interests you, it may be worth seeing what else is out there through the 42 healthcare AI stocks

Natera now sits near its recent highs after a sharp rerating, so the key issue is whether recent wins are already fully reflected in the US$309.93 share price or if the valuation still leaves meaningful upside.

Most Popular Narrative: 9.8% Overvalued

Natera is trading at $309.93 compared with a most followed narrative fair value of $282.14, so the story assumes a lot is already going right.

Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera). This will likely boost top-line revenue.

Curious what has to happen for that fair value to stack up. The narrative leans on brisk revenue growth, rising margins, and a rich future earnings multiple. Want the full blueprint behind those assumptions.

Result: Fair Value of $282.14 (OVERVALUED)

However, there are still clear weak points in the Natera narrative if heavy R&D and SG&A spending persists or competitive pressure squeezes pricing power and volumes.

Another View on Natera’s Valuation

While the crowd narrative has Natera trading about 9.8% above its US$282.14 fair value, the Simply Wall St DCF model points in the other direction. On that measure, the stock at US$309.93 sits around 48.9% below an estimated future cash flow value of US$607.06. That is a wide gap for investors to think through.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around Natera so far, it makes sense to review the full picture for yourself and move quickly while sentiment is active, including its 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Natera?

If Natera has caught your attention, do not stop here. Broaden your watchlist with fresh ideas across quality, income and potential upside so you are not leaving options on the table.

• Spot potential bargains early by scanning screener containing 20 high quality undiscovered gems and see which underfollowed stocks still pair strong fundamentals with room for attention.
• Build a sturdier core in your portfolio by focusing on companies from the solid balance sheet and fundamentals stocks screener (51 results) that couple financial strength with resilient business profiles.
• Strengthen your income stream by searching through the 10 dividend fortresses that aim for higher yields backed by more robust fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.